Trial Profile

Efficacy of minodronate and denosumab for bone loss in patients with prostate cancer undergoing androgen deprivation therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denosumab (Primary) ; Minodronic acid (Primary) ; Alfacalcidol
Indications Metabolic bone diseases; Osteoporosis
Focus Therapeutic Use
Acronyms PROMADE

Most Recent Events

09 Dec 2020 Status changed from active, no longer recruiting to completed.
09 Jul 2019 Planned number of patients changed from 150 to 99.
10 Mar 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com